Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Alessandra Bandera, Elisa Colella, Giuliano Rizzardini, Andrea Gori & Mario Clerici. (2017) Strategies to limit immune-activation in HIV patients. Expert Review of Anti-infective Therapy 15:1, pages 43-54.
Read now
Read now
Philip M. Grant, Douglas Kitch, Grace A. McComsey, Camlin Tierney, Belinda Ha & Todd T. Brown. (2015) Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults. HIV Clinical Trials 16:2, pages 66-71.
Read now
Read now
Mary Sugden & Mark Holness. (2011) Management of dyslipidemia in HIV-infected patients. Clinical Lipidology 6:4, pages 447-462.
Read now
Read now
Adrian Curran & Esteban Ribera. (2011) From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir. Expert Opinion on Drug Safety 10:3, pages 389-406.
Read now
Read now
Maria Dimitrova, Guenka Petrova, Tatiana Cervenjakova, Nina Jancheva, Mona Stefanova, Manoela Manova, Alexandra Savova & Assena Stoimenova. (2011) Budget Impact Model of New Antiretroviral Biotechnology Medicines for Treatment of HIV/AIDS Patients in Bulgaria. Biotechnology & Biotechnological Equipment 25:3, pages 2547-2554.
Read now
Read now
Esteban Ribera, José Carlos Paradiñeiro, Adria Curran, Silvia Sauleda, Elena García-Arumí, Eva Castella, Carolina Puiggròs, Manuel Crespo, Maria Feijoo, Marjorie Diaz, Sara Villar del Saz, Merçè Planas, Delia Sureda, Vicenç Falcó, Imma Ocaña & Albert Pahissa. (2008) Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study). HIV Clinical Trials 9:6, pages 407-417.
Read now
Read now
MT Bennett, KW Johns & GP Bondy. (2008) Current and future treatments of HIV-associated dyslipidemia. Future Lipidology 3:2, pages 175-188.
Read now
Read now
Articles from other publishers (47)
Federica Fogacci, Enrico Strocchi, Maddalena Veronesi, Claudio Borghi & Arrigo F. G. Cicero. (2020) Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials. Marine Drugs 18:6, pages 292.
Crossref
Crossref
Shujing Ji, Yufan Xu, Dating Han, Xiuming Peng, Xiangyun Lu, Norbert H. Brockmeyer & Nanping Wu. (2019) Changes in Lipid Indices in HIV+ Cases on HAART. BioMed Research International 2019, pages 1-8.
Crossref
Crossref
David V Glidden, Kathleen Mulligan, Vanessa McMahan, Peter L Anderson, Juan Guanira, Suwat Chariyalertsak, Susan P Buchbinder, Linda-Gail Bekker, Mauro Schechter, Beatriz Grinsztejn & Robert M Grant. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical Infectious Diseases 67:3, pages 411-419.
Crossref
Crossref
Rosario Martinez-Vega, Nicole L De La Mata, Nagalingeswaran Kumarasamy, Penh Sun Ly, Kinh Van Nguyen, Tuti P Merati, Thi Thanh Pham, Man Po Lee, Jun Yong Choi, Jeremy L Ross & Oon Tek Ng. (2018) Durability of Antiretroviral Therapy Regimens and Determinants for Change in HIV-1-Infected Patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). Antiviral Therapy 23:2, pages 167-178.
Crossref
Crossref
Willard Tinago, Aoife G. Cotter, Caroline A. Sabin, Alan Macken, Eoin Kavanagh, Jennifer J. Brady, Geraldine McCarthy, Juliet Compston & Patrick W.G. Mallon. (2017) Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients. AIDS 31:5, pages 643-652.
Crossref
Crossref
Philip M. Grant, Douglas Kitch, Grace A. McComsey, Ann C. Collier, Susan L. Koletar, Kristine M. Erlandson, Michael T. Yin, Benedetta Bartali, Belinda Ha, Kathy Melbourne & Todd T. Brown. (2016) Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. Journal of Infectious Diseases 214:4, pages 607-611.
Crossref
Crossref
Nay Thiha, Palanivel Chinnakali, Anthony D. Harries, Myint Shwe, Thanumalaya Perumal Balathandan, Sai Thein Than Tun, Mrinalini Das, Htay Htay Tin, Yi Yi, François Xavier Babin, Thi Thi Lwin & Philippe Albert Clevenbergh. (2016) Is There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar. PLOS ONE 11:8, pages e0160616.
Crossref
Crossref
Philip M. Grant & Aoife G. Cotter. (2016) Tenofovir and bone health. Current Opinion in HIV and AIDS 11:3, pages 326-332.
Crossref
Crossref
Denise C. Hsu & Irini Sereti. (2016) Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs 76:5, pages 533-549.
Crossref
Crossref
Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason A. Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph Custodio, Andrew Cheng & Scott McCallister. (2015) Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 69:4, pages 439-445.
Crossref
Crossref
E Martínez, E Ribera, B Clotet, V Estrada, J Sanz, J Berenguer, R Rubio, F Pulido, M Larrousse, A Curran, E Negredo, S Arterburn, P Ferrer & ML Álvarez. (2015) Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio. HIV Medicine 16:6, pages 370-374.
Crossref
Crossref
Corinne Isnard Bagnis & Hans-Jürgen Stellbrink. (2015) Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review. Infectious Diseases and Therapy 4:1, pages 15-50.
Crossref
Crossref
Laurence Slama, Xiuhong Li, Todd Brown, Lisa P. Jacobson, Gilles Pialoux, Bernard Macatangay, Robert K. Bolan, John Phair & Frank J. Palella. (2014) Increases in Duration of First Highly Active Antiretroviral Therapy Over Time (1996–2009) and Associated Factors in the Multicenter AIDS Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 65:1, pages 57-64.
Crossref
Crossref
. (2013) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013). Enfermedades Infecciosas y Microbiología Clínica 31:9, pages 602.e1-602.e98.
Crossref
Crossref
Mikaela Smit, Colette Smit, Suzanne Geerlings, Luuk Gras, Kees Brinkman, Timothy B. Hallett & Frank de Wolf. (2013) Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands. PLoS ONE 8:9, pages e76071.
Crossref
Crossref
Giovanni Guaraldi, Chiara Stentarelli, Stefano Zona & Antonella Santoro. (2013) HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy. Drugs 73:13, pages 1431-1450.
Crossref
Crossref
Shobhit Jain, Ninad Desai & Amrit Bhangoo. (2013) Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. Reviews in Endocrine and Metabolic Disorders 14:2, pages 113-118.
Crossref
Crossref
Jason J. Schafer, Kristine Manlangit & Kathleen E. Squires. (2013) Bone Health and Human Immunodeficiency Virus Infection. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:6, pages 665-682.
Crossref
Crossref
Denise C Hsu, Irini Sereti & Jintanat Ananworanich. (2013) Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Research and Therapy 10:1, pages 29.
Crossref
Crossref
. (2012) Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012). Enfermedades Infecciosas y Microbiología Clínica 30:6, pages e1-e89.
Crossref
Crossref
Adrian Curran, Esteban Martinez, Daniel Podzamczer, Montserrat Lonca, Patricia Barragan, Manuel Crespo, Vicenç Falco, Sergio Vidal-Sicart, Arkaitz Imaz, Maria Martinez, Jose Maria Gatell & Esteban Ribera. (2012) Changes in Body Composition and Mitochondrial Dna in HIV-1-Infected Patients Switching to Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine: A Substudy of the Bicombo Trial. Antiviral Therapy 17:4, pages 711-718.
Crossref
Crossref
Carolyn D Amole, Catherine Brisebois, Shaffiq Essajee, Erin Koehler, Andrew D Levin, Meredith C Moore, David H Brown Ripin, Joanna J Sickler & Inder R Singh. (2011) Optimizing Antiretroviral Product Selection: A Sample Approach to Improving Patient Outcomes, Saving Money, and Scaling-up Health Services in Developing Countries. JAIDS Journal of Acquired Immune Deficiency Syndromes 57:Supplement 2, pages S100-S103.
Crossref
Crossref
E.R. Feeney & P.W.G. Mallon. (2011) Insulin resistance in treated HIV infection. Best Practice & Research Clinical Endocrinology & Metabolism 25:3, pages 443-458.
Crossref
Crossref
L. MagentaS. Dell-KusterW.O. RichterJ. YoungB. HasseM. FleppB. HirschelP. VernazzaJ. EvisonM. CavassiniL.A. DecosterdH.C. BucherE. Bernasconi, and the Swiss HIV Cohor. (2011) Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. AIDS Research and Human Retroviruses 27:5, pages 525-533.
Crossref
Crossref
Allison C RossGrace A McComsey. (2011) Assessment and modification of cardiovascular disease risk in the HIV-infected individual. Future Virology 6:3, pages 307-320.
Crossref
Crossref
Heidi M Crane, Carl Grunfeld, James H Willig, Michael J Mugavero, Stephen Van Rompaey, Richard Moore, Benigno Rodriguez, Betsy J Feldman, Michael M Lederman, Michael S Saag & Mari M Kitahata. (2011) Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 25:2, pages 185-195.
Crossref
Crossref
Jordan E Lake & Judith S Currier. (2010) Switching antiretroviral therapy to minimize metabolic complications. HIV Therapy 4:6, pages 693-711.
Crossref
Crossref
Sara Melzi, Laura Carenzi, Maria Vittoria Cossu, Simone Passerini, Amedeo Capetti & Giuliano Rizzardini. (2010) Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. Cholesterol 2010, pages 1-13.
Crossref
Crossref
Marisa Tungsiripat, Douglas Kitch, Marshall J Glesby, Samir K Gupta, John W Mellors, Laura Moran, Lynne Jones, Beverly Alston-Smith, James F Rooney & Judith A Aberg. (2010) A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24:11, pages 1781-1784.
Crossref
Crossref
Carl Grunfeld, Michael Saag, Joseph Cofrancesco, Cora Elizabeth Lewis, Richard Kronmal, Steven Heymsfield, Phyllis C Tien, Peter Bacchetti, Michael Shlipak & Rebecca Scherzer. (2010) Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 24:11, pages 1717-1726.
Crossref
Crossref
Panel de expertos de Gesida & Plan Nacional sobre el Sida. (2010) Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010). Enfermedades Infecciosas y Microbiología Clínica 28:6, pages 362.e1-362.e91.
Crossref
Crossref
José M. Gatell Artigas. (2010) Infección por el virus de la inmunodeficiencia humana tipo 1: errores irreversibles que no deberíamos volver a cometer. Medicina Clínica 134:9, pages 399-401.
Crossref
Crossref
Emilie Degris, Cyrille Delpierre, Agnès Sommet, Stèphane Sire, Slim Lassoued, Christian Aquilina, Bruno Marchou, Patrice Massip, Martine Obadia, Fabrice Marion-Latard, Eric Bonnet & Jacques Bernard. (2010) Longitudinal Study of Body Composition of 101 HIV Men With Lipodystrophy: Dual-Energy X-Ray Criteria for Lipodystrophy Evolution. Journal of Clinical Densitometry 13:2, pages 237-244.
Crossref
Crossref
M. A. Valantin, R. Bittar, P. de Truchis, D. Bollens, L. Slama, P. Giral, D. Bonnefont-Rousselot, P. Petour, C. Aubron-Olivier, D. Costagliola & C. Katlama. (2010) Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. Journal of Antimicrobial Chemotherapy 65:3, pages 556-561.
Crossref
Crossref
Philip M. Grant, Sarah Palmer, Eran Bendavid, Annie Talbot, Debbie C. Slamowitz, Pat Cain, Stacy S. Kobayashi, Maya Balamane & Andrew R. Zolopa. (2009) Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: Effects on level of residual viremia and quality of life. Journal of Clinical Virology 46:4, pages 305-308.
Crossref
Crossref
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, pages 910-928.
Crossref
Crossref
John A Bartlett & John F Shao. (2009) Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. The Lancet Infectious Diseases 9:10, pages 637-649.
Crossref
Crossref
Leonardo CalzaRoberto ManfrediVincenzo ColangeliDaria PocaterraNirmala RossetiMichele PavoniFrancesco Chiodo. (2009) Efficacy and Safety of Atazanavir-Ritonavir Plus Abacavir-Lamivudine or Tenofovir-Emtricitabine in Patients with Hyperlipidaemia Switched from a Stable Protease Inhibitor-Based Regimen Including One Thymidine Analogue. AIDS Patient Care and STDs 23:9, pages 691-697.
Crossref
Crossref
Edwin DeJesus, Benjamin Young, Javier O Morales-Ramirez, Louis Sloan, Douglas J Ward, John F Flaherty, Ramin Ebrahimi, Jen-Fue Maa, Karen Reilly, Janet Ecker, Damian McColl, Daniel Seekins & Awny Farajallah. (2009) Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:2, pages 163-174.
Crossref
Crossref
Judith A. Aberg. (2009) Lipid Management in Patients Who Have HIV and Are Receiving HIV Therapy. Endocrinology and Metabolism Clinics of North America 38:1, pages 207-222.
Crossref
Crossref
M. RodríguezB. DanielsS. GunawardeneG.K. Robbins. (2009) High Frequency of Vitamin D Deficiency in Ambulatory HIV-Positive Patients. AIDS Research and Human Retroviruses 25:1, pages 9-14.
Crossref
Crossref
Jean-Luc Meynard, Karine Lacombe, Jean-Marie Poirier, Olivier Massot, Bénédicte Lefebvre, Olivier Bouchaud, Jean-Baptiste Guiard-Schmidt, Alvaro Martinez, Pascale Benlian & Pierre-Marie Girard. (2008) Sustained Increase of HDL Cholesterol Over a 72-Week Period in HIV-Infected Patients Exposed to an Antiretroviral Regimen Including Lopinavir/Ritonavir. Journal of the International Association of Physicians in AIDS Care 7:6, pages 311-316.
Crossref
Crossref
Todd T. Brown. (2008) Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy. The Journal of Clinical Endocrinology & Metabolism 93:8, pages 2937-2945.
Crossref
Crossref
Joaquín Portilla. (2008) Tenofovir como estrategia para evitar o detener efectos adversos. Enfermedades Infecciosas y Microbiología Clínica 26, pages 19-24.
Crossref
Crossref
José Ignacio Bernardino de la Serna, Marta Mora Rillo & José Ramón Arribas López. (2008) Datos clínicos I. Experiencia clínica de tenofovir en combinaciones con inhibidores no análogos de la transcriptasa inversa. Enfermedades Infecciosas y Microbiología Clínica 26, pages 7-12.
Crossref
Crossref
Esteban Ribera Pascuet & Adria Curran. (2008) Papel actual de tenofovir en la cl?nica. Enfermedades Infecciosas y Microbiolog?a Cl?nica 26, pages 45-54.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:6.
Crossref
Crossref